Pharma companies in a flux over Trump's 200% tariff move on generics
US President Donald Trump announced 100% tariffs on generic medicines from Aug 2028 and 200% from Aug 2029, unless companies move manufacturing to the US.
India supplies 47% of generic prescriptions in the US and ships $10 billion in pharma exports there, making it heavily exposed.
A two-year exemption window gives Indian exporters time to adjust supply chains, but industry experts see the move as a negotiating lever.
Companies like Sun Pharma, Dr Reddy's Labs, and Cipla, with 35-50% US revenue, face higher impact but some have US facilities to mitigate.
High tariffs could raise US medicine prices and cause shortages, as key ingredients come from China and India, not replicable quickly in the US.
Story angle
Center-right
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Times of India
Center-right
Mixed factuality
Who owns this?
Times Group
Bennett, Coleman & Co. (Sahu Jain family)
India's largest newspaper group by circulation.
Wikipedia: Sahu Jain family